<DOC>
	<DOCNO>NCT02802137</DOCNO>
	<brief_summary>The study investigate 24-hour efficacy ocular surface health preservative-free tafluprost combine preservative-free regimen ( tafluprost dorzolamide/timolol fix combination ) open-angle glaucoma patient insufficiently control latanoprost monotherapy show sign , symptom ocular surface disease preservative-containing latanoprost monotherapy . This trial randomize open-angle glaucoma patient insufficiently control ( IOP &gt; 20 mm Hg ) brand , generic latanoprost monotherapy require IOP reduction demonstrate clinical sign , symptom ocular surface disease .</brief_summary>
	<brief_title>24-hour Efficacy Ocular Surface With Talfuprost Triple Combined Therapy</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Dorzolamide</mesh_term>
	<criteria>Inclusion criterion Openangle glaucoma patient ( primary openangle glaucoma , exfoliative , pigmentary glaucoma ) insufficiently control brand , generic latanoprost monotherapy ( IOP &gt; 20 mm Hg determine 2 separate IOP measurement 10:00 ± 1 hour ) Patients sign , symptom ocular surface disease . Only openangle glaucoma subject , accord opinion principal investigator , require IOP reduction . Patients must demonstrate least 20 % IOP reduction 10:00 ( ± 1 hour ) treat brand , generic latanoprost monotherapy least 3 month . Only subject openangle glaucoma exhibit ( prior latanoprost therapy ) untreated , sit IOP evaluate Goldmann tonometry 2539 mm Hg 10:00 ( ± 1 hour ) . Age 2185 year Mild moderate glaucomatous disc damage visual field loss ( le 12 dB mean deviation visual field loss attribute glaucoma Those 0.8 well vertical cuptodisc ratio visual acuity great 0.1 study eye . Open anterior chamber angle . Those demonstrate reliable visual field ( least two visual field le 20 % fixation loss , false positive , negative ) Patients understand study instruction , willing attend followup appointment comply study medication usage . Exclusion criteria Patients history le 10 % IOP decrease IOPlowering medication . Those evidence concurrent conjunctivitis , keratitis , uveitis either eye . Subjects history inadequate adherence ; intolerance , contraindication either prostaglandin , βblockers , dorzolamide , benzalconium chloride ( BAK ) Patients severe ocular surface disease , previous intraocular conventional laser surgery study eye ( within 6 month prior enrolment ) ; previous history ocular trauma ; use corticosteroid ( within 3 month enrolment ) use contact lens . Those baseline examination show clinical evidence inflammation , sign ocular infection ( except blepharitis ) , sign corneal abnormality affect subsequent IOP measurement Subjects show unwillingness participate trial . Females childbearing potential lactating mother .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>tafluprost</keyword>
	<keyword>dorzolamide</keyword>
	<keyword>timolol</keyword>
	<keyword>FC</keyword>
</DOC>